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ABSTRACT
Objective: The superiority of drug-eluting stents
(DES) over bare-metal stents (BMS) in patients with ST
elevation myocardial infarction (STEMI) is well studied;
however, randomised data in patients with non-ST
elevation myocardial infarction (NSTEMI) are lacking.
The objective of this study was to investigate whether
stenting with everolimus-eluting stents (EES) safely
reduces restenosis in patients with NSTEMI as
compared to BMS.
Methods: ELISA-3 patients were asked to participate
in the angiographic substudy and were randomised to
DE (Xience V) or BM (Vision) stenting (ELISA-3
group). The primary end point was minimal luminal
diameter (MLD) at 9-month follow-up angiography. In
addition, 296 patients with NSTEMI who were excluded
or did not want to participate in the ELISA-3 trial (RELI
group) were randomised to DE or BM stenting and
underwent clinical follow-up only (major adverse
cardiac events (MACE), stent thrombosis (ST)). A
pooled analysis was performed to assess an effect on
clinical outcome.
Results: 178 of 540 ELISA-3 patients participated in
the angiographic substudy. MLD at 9 months
angiography was 2.37±0.63 mm (DES) versus 1.84
±0.62 mm (BMS), p<0.001. Binary restenosis occurred
in 1.9% in the DES group versus 16.7% in the BMS
group (RR 0.11, 95% CI 0.02 to 0.84, p=0.007). In the
pooled analysis, the incidence of MACE, target vessel
revascularisation and ST at 2 years follow-up in the
DES versus BMS group was 12.5% versus 16.0%
(p=0.28), 4.0% versus 10.4% (p=0.009) and 1.3%
versus 3.0% (p=0.34), respectively.
Conclusions: In patients with NSTEMI, use of EES is
safe and decreases both angiographic and clinical
restenosis as compared to BMS http://www.isrctn.com/
search?q=39230163.
Trial registration number: 39230163; Post-results.
INTRODUCTION
Percutaneous coronary intervention with bare
metal stent implantation is associated with
high restenosis rates as compared to the ﬁrst-
generation drug-eluting stents (DES).1–4 The
second-generation everolimus-eluting stent
(EES) has shown a strong antiproliferative
effect with a non-inferior efﬁcacy proﬁle com-
pared to the ﬁrst-generation DES but with an
improved safety proﬁle. While the effect of
DE versus BM stenting in STelevation myocar-
dial infarction (STEMI) populations has been
extensively evaluated, consistently showing
that the second-generation DES are as safe as
bare-metal stents (BMS) in terms of stent
thrombosis while reducing restenosis rates,5–8
there are no randomised studies comparing
DES versus its BMS counterpart in the setting
of non-STEMI (NSTEMI). This subset of
patients, however, comprises up to 50% of
patients included in some stent trials, particu-
larly those with an all-comer design. This evi-
dence has translated into a class I, level of
evidence a recommendation in current
KEY QUESTIONS
What is already known about this subject?
▸ The superiority of drug-eluting stents (DES) over
bare-metal stents (BMS) in patients with ST eleva-
tion myocardial infarction (STEMI) is well studied.
What does this study add?
▸ This trial provides randomised data, showing
that also in non-STEMI (NSTEMI),
everolimus-eluting stents are safe and decrease
restenosis compared to BMS.
How might this impact on clinical practice?
▸ Considering that randomised data on usage of
second-generation DES in patients with NSTEMI
are scarce, our study provides more evidence
that our current clinical practice of treating
patients with STEMI with DES is safer and more
efficient than treating with BMS.
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clinical guidelines for the use of new-generation DES
over BMS.9
Montalescot et al10 demonstrated that patients with
STEMI and NSTEMI have similar in hospital and long-
term prognoses as well as similar independent correlates
of outcome, despite different in-hospital management and
despite differences in lesion pathology. In STEMI, the
culprit artery is usually occluded by a red thrombus,
whereas in NSTEMI the culprit artery is usually patent with
a non-occlusive white thrombus. Also, patient character-
istics differ; the NSTEMI population is older, has a higher
cardiovascular risk proﬁle more often with diabetes and
hypertension. Patients with NSTEMI have more extensive
coronary artery disease than patients with STEMI and
more often a personal history of coronary heart disease.11
In this randomised study, we focus on the effects of
the use of an EES on the incidence of restenosis and on
long-term safety in terms of MACE in this population
with NSTEMI, treated with either DES or its bare metal
counterpart.
METHODS
In this article, we describe the results of the ELISA-3
angiographic substudy and the ELISA prospective
Registry (RELI).
The rationale, design and primary results of ELISA-3
have been previously described.12
Brieﬂy, the ELISA-3 trial is a prospective multicentre
randomised controlled trial, in which 542 patients, hos-
pitalised with non-ST elevation acute coronary syndrome
(NSTE-ACS), were randomised to either an immediate
(angiography and revascularisation if appropriate<12
hour) or a delayed invasive strategy (>48 hour after ran-
domisation). This prespeciﬁed substudy investigates
whether stenting with EES safely decreases the incidence
of restenosis, compared to stenting with a BMS with the
same stent frame design.
Patients were eligible if they were hospitalised with ischae-
mic chest pain or dyspnoea at rest, with the last episode
occurring 24 hours or less before randomisation, and had
at least two of three of the following high-risk character-
istics: (1) evidence of extensive myocardial ischaemia on
ECG (shown by new cumulative ST depression >5 mm or
temporary ST segment elevation in two contiguous leads
<30 min), (2) elevated biomarkers (troponin T >0.10 μg/L
or myoglobin >150 μg/L) or elevated CKMB fraction (>6%
of total CK), (3) age above 65 years. Exclusion criteria were
persistent ST segment elevation, symptoms of ongoing myo-
cardial ischaemia despite optimal medical therapy, contra-
indication for diagnostic angiography, active bleeding,
cardiogenic shock, acute posterior infarction and life
expectancy <1 year.
During the same study period, patients with NSTEMI
who did not want to participate in, or who did not meet
the inclusion criteria for, high-risk NSTEMI of the
ELISA-3 study, were recruited in the ELISA prospective
registry.
Both patients in the ELISA-3 trial and in the ELISA
registry, who underwent coronary angiography and were
deemed appropriate for percutaneous coronary inter-
vention (PCI) and stenting, underwent randomisation in
the catheterisation laboratory to either EE or BM stent-
ing. Patients with multiple lesions in need of more than
one stent were treated with the same type of stent for all
lesions.
Patients received dual antiplatelet therapy (acetylsa-
licic acid and clopidogrel) for the duration of 1 year.
Between July 2007 and June 2012, 542 patients were
randomised in the ELISA-3 trial. About 344 of these
patients were eligible for PCI and 178 of these patients
underwent a second randomisation to EES (n=87) and
BMS (n=91). In the same period, 296 patients in the
ELISA registry group were also randomised (EES n=147,
BMS n=149). Patients in the ELISA-3 group were
planned to undergo coronary angiography at 9 months,
whereas patients in the prospective registry were fol-
lowed for 2 years for clinical end points without planned
follow-up angiography (ﬁgure 1).
The trial was conducted in six Dutch hospitals of which
one had 24 hour facilities for (primary) PCI and coron-
ary artery bypass graft (CABG) surgery. The study com-
plied with the Declaration of Helsinki, was approved by
the ethics committee of Isala, Zwolle, the Netherlands,
and all patients gave written informed consent before
entering the study or the registry. The study was regis-
tered in the ISRCTN Register (ISRCTN39230163).
Randomisation and treatment
Patients were randomised by a closed envelope system to
blinded stent designs. Operators were blinded to the
device used and the clinical end points were adjudicated
by investigators blinded with regard to patients’ treat-
ment allocation (ﬂow chart: summary of the study
design). Coronary angioplasty was performed according
to the local standards of the intervention centre. All
patients were treated according to the guidelines.
Concomitant medication included a loading dose of
aspirin (500 mg orally or intravenously), clopidogrel
(600 mg orally) and 5000 IU unfractionated heparin
intravenously as soon as possible after diagnosis.
Tiroﬁban (bolus of 25 mg/kg followed by continuous
infusion of 0.15 mg/min/kg), nitrates, β-blockers and
calcium channel blockers were given at the discretion of
the investigator.
Definitions
Procedure time was deﬁned as the time interval between
placement of the arterial sheath and removal of the
guiding catheter. Clinical procedural success was
deﬁned as immediate angiographic success (deﬁned as
a diameter stenosis postprocedure of <50% (visual
assessment) and TIMI 3 ﬂow) without major in-hospital
complication, including death, myocardial infarction
(MI), stent thrombosis or emergency coronary artery
bypass surgery. MI was deﬁned by the presence of new
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Q waves or creatine kinase level or MB fraction at least
twice the upper limit of normal. Lesions were classiﬁed
according to the deﬁnitions recommended by the
American College of Cardiology/American Heart
Association task force.
Stent thrombosis was deﬁned as complete occlusion of
the stented lesion at follow-up angiography or at recur-
rent angiography performed because of recurrent chest
pain and signs of ischaemia.
End points
The primary end point of the ELISA-3 angiographic sub-
study was the extent of restenosis, expressed by the dif-
ference in minimal luminal diameter at 9-month
follow-up angiography, as assessed by an independent
core laboratory.
We conducted a pooled analysis of the ELISA-3 and
the prospective ELISA registry patients, in which the
incidence of deﬁnite stent thrombosis at 2 years
follow-up was the key secondary and safety end point.
The incidence of MACE at 2 years follow-up was an
exploratory end point in this pooled analysis.
Qualitative and quantitative coronary analysis
Coronary angiograms were performed before angio-
plasty, immediately after angioplasty and at 9-month
follow-up. Standard acquisition procedures were fol-
lowed for qualitative and quantitative coronary angiog-
raphy analysis. To improve the accuracy and
reproducibility of measurements, intracoronary
isosorbide-dinitrate (1–3 mg) was given before the initial
and ﬁnal post-stent placement angiograms.
Angiographies were recorded on a CD-ROM. Matched
orthogonal views were used for quantitative analysis at
each control. Dye-ﬁlled guiding catheters were used for
magniﬁcation calibration. Data collection included
assessment of TIMI ﬂow grade, lesion eccentricity, esti-
mation of thrombus load and AHA/ACC classiﬁcation.
An independent laboratory (DIAGRAM, Zwolle, the
Netherlands) performed routine quantitative coronary
angiography measurements using the Coronary
Angiography Analysis System (CAAS II System). Two
orthogonal angiographic views with minimised vessel
foreshortening were obtained, and the angiogram
showing the most severe stenosis was selected for quanti-
tative coronary analysis. Postprocedure and follow-up
angiograms, which duplicate the initial orthogonal
views, were obtained after the removal of the balloon
and guidewire.
Follow-up
Coronary angiography was planned at 9 months in the
ELISA-3 angiographic substudy patients. Coronary angi-
ography could be prematurely performed on the basis
of clinical indications; it was used as the follow-up angio-
gram in the case of restenosis or if performed after
4 months. When it was performed within 4 months’ time
without evidence of restenosis, angiographic control was
repeated at 9 months. All major clinical events including
death, MI, readmission to hospital for unstable angina
pectoris and the need for additional (ischaemia driven)
revascularisation of the target vessel were monitored at
the time of repeated angiography or by phone at 9 and
24 months for all patients and adjudicated by two inde-
pendent physicians blinded to randomised treatment.
Statistical analysis
The study is designed to demonstrate superiority of EES
based on the assumption that at follow-up angiography
minimal luminal diameter (MLD) coated—MLD non-
coated >0.20 mm (H0: MLD coated # MLD non-coated
—0.20, H1: MLD coated >MLD non-coated—0.20).
Previous studies have shown that it is reasonable to
assume that the MLD measurement after angioplasty
follows a normal distribution. It is expected that in all
groups the mean will be ∼1.9 mm and the SD will be
∼0.5 mm. Allowing for a type I error of 5% and a
dropout rate of 20%, a sample of 280 patients (140 per
group) will give 85% power to prove superiority of
Figure 1 Flow diagram of study
design. BMS, bare-metal stent;
EES, everolimus-eluting stent;
MACE, major adverse cardiac
events (composite of death,
myocardial infarction and target
vessel revascularisation); PCI,
percutaneous coronary
intervention.
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coated stenting compared to the use of a non-coated
stent.
Data were analysed according to the intention-to-treat
analysis. Continuous variables were expressed as means
±SD and were compared between the intervention
groups using a Mann-Whitney U test. Categorical data
were described by proportions and compared with the
χ2 or Fisher’s exact test. Logistic regression was used to
calculate the p value of the interaction between the
effect of the intervention and the prespeciﬁed sub-
groups on the primary end point. All tests were two-
sided and an α of 5% was used. Statistical analysis was
performed with SPSS (V.20); SPSS, Chicago, Illinois,
USA
MACE survival Kaplan-Meier curves were obtained
and compared by means of the log-rank test.
RESULTS
Baseline characteristics
Between July 2007 and June 2012, 178 ELISA-3 patients
(87 EES, 91 BMS) and 296 ELISA registry patients (147
EES, 149 BMS) were randomised. Baseline character-
istics in the ELISA-3 population were well balanced
between the treatment groups (table 1). There was a sig-
niﬁcant difference in age between ELISA-3 and the
ELISA registry group (68.0±10.9 vs 63.6±12.5 years,
p<0.001); other baseline characteristics did not differ
between Elisa-3 and the registry group (tables 2 and 3).
Angiographic outcome
Follow-up angiography was performed at 9 months in
124 (70%) of the ELISA-3 patients. Baseline character-
istics of patients who declined follow-up angiography
were similar to those of patients who had a follow-up
angiography. The primary end point, the degree of
restenosis (MLD), was signiﬁcantly different when com-
paring DES to BMS (2.37±0.63 mm vs 1.84±0.62 mm,
p<0.001) (table 4). The incidence of binary restenosis,
deﬁned as a diameter stenosis at 9 months follow-up of
more than 50%, was 1.9% in the DES group vs 16.7% in
the BMS group (RR 0.11, 95% CI (0.02 to 0.84),
p=0.01).
Clinical outcome
In the ELISA-3 group, clinical follow-up at 24 months
was complete in 173 (97%) patients.
The rate of MACE was 10.7% (EES) versus 14.6%
(BMS) p=0.442. Target vessel revascularisation was neces-
sary in 4.8% (EES) versus 11.2% (BMS) p=0.119 and
stent thrombosis occurred in 1.2% (EES) versus 3.4%
(BMS) p=0.621.
Table 1 Characteristics and history (Elisa-3)
Total EES BMS p Value
Male gender 136/178 (76.4%) 70/87 (80.5%) 66/91 (72.5%) 0.213
Hypertension 91/178 (51.1%) 44/87 (50.6%) 47/91 (51.6%) 0.886
Previous MI 28/178 (15.7%) 14/87 (16.1%) 14/91 (15.4%) 0.897
Previous CABG 22/178 (12.4%) 9/87 (10.3%) 13/91 (14.3%) 0.425
Previous PCI 30/178 (16.9%) 13/87 (14.9%) 17/91 (18.7%) 0.505
Previous stroke 6/178 (3.4%) 1/87 (1.1%) 5/91 (5.5%) 0.211
Previous TIA 8/178 (4.5%) 1/87 (1.1%) 7/91 (7.7%) 0.066
Diabetes Mellitus 34/178 (19.1%) 17/87 (19.5%) 17/91 (18.7%) 0.884
Smoking 53/178 (29.8%) 28/87 (32.2%) 25/91 (27.5%) 0.492
Family history 72/176 (40.9%) 32/85 (37.6%) 40/91 (44.0%) 0.395
BMS, bare-metal stent; CABG, coronary artery bypass graft; EES, everolimus-eluting stent; MI, myocardial infarction; PCI, percutaneous
coronary intervention; TIA, transient ischaemic attack.
Table 2 Characteristics and history by study
Total Elisa-3 Elisa registry p Value
Randomisation everolimus 234/474 (49.4%) 87/178 (48.9%) 147/296 (49.7%) 0.868
Male gender 351/474 (74.1%) 136/178 (76.4%) 215/296 (72.6%) 0.365
Hypertension 226/474 (47.7%) 91/178 (51.1%) 135/296 (45.6%) 0.244
Previous MI 69/473 (14.6%) 28/178 (15.7%) 41/295 (13.9%) 0.584
Previous CABG 47/474 (9.9%) 22/178 (12.4%) 25/296 (8.4%) 0.167
Previous PCI 70/474 (14.8%) 30/178 (16.9%) 40/296 (13.5%) 0.321
Previous stroke 21/474 (4.4%) 6/178 (3.4%) 15/296 (5.1%) 0.385
Previous TIA
Diabetes Mellitus 85/474 (17.9%) 34/178 (19.1%) 51/296 (17.2%) 0.607
Smoking 167/473 (35.3%) 53/178 (29.8%) 114/295 (38.6%) 0.051
Family history 200/472 (42.4%) 72/176 (40.9%) 128/296 (43.2%) 0.620
CABG, coronary artery bypass graft; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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In the registry group, clinical follow-up at 24 months
was complete in 282 (95%) patients. The rate of MACE
was 13.6% (EES) versus 16.9% (BMS) p=0.437. Target
vessel revascularisation was necessary in 3.6% (EES)
versus 9.9% (BMS) p=0.035 and stent thrombosis
occurred in 1.4% (EES) versus 2.8% (BMS) p=0.684.
The secondary end point, stent thrombosis, in the
pooled population (1.3% (DES) versus 3.0% (BMS),
p=0.339) did not differ signiﬁcantly between the groups at
2 years follow-up. Neither did the exploratory end point
MACE (12.5% (DES) versus 16.0% (BMS), p=0.284)
(table 3), as also illustrated by the Kaplan-Meier event-free
survival curves (ﬁgures 2 and 3). DE stenting, however, sig-
niﬁcantly reduced target vessel revascularisation as com-
pared to BM stenting (4.0% vs 10.4%, p=0.009) (table 5).
DISCUSSION
The main ﬁnding of this study was that the use of an
everolimus eluting second-generation DES is safe and
decreased restenosis, angiographic as well as clinical, in
patients with NSTEMI.
Table 3 Characteristics and history (pooled analysis)
EES (N=234) BMS (N=240) p Value
Age, years (mean±SD) 65.91±11.69 64.63±12.24 0.288
Male gender 176/234 (75.2%) 175/240 (72.9%) 0.627
Hypertension 110/234 (47.0%) 116/240 (48.3%) 0.773
Previous MI 36/233 (15.5%) 33/240 (13.8%) 0.600
Previous CABG 21/234 (9.0%) 26/240 (10.8%) 0.498
Previous PCI 37/234 (15.8%) 33/240 (13.8%) 0.527
Previous stroke 12/234 (5.1%) 9/240 (3.8%) 0.466
Previous TIA 1/87 (1.1%) 7/91 (7.7%) 0.065
Diabetes mellitus 45/234 (19.2%) 40/240 (16.7%) 0.467
Smoking 81/234 (34.6%) 86/239 (36.0%) 0.756
Family history 97/232 (41.8%) 103/240 (42.9%) 0.808
Infarct-related vessel 0.934
RCA 61/232 (26.3%) 68/240 (28.3%)
LAD 93/232 (40.1%) 89/240 (37.1%)
CX 61/232 (26.3%) 62/240 (25.8%)
Graft 15/232 (6.5%) 18/240 (7.5%)
LM 2/232 (0.9%) 3/240 (1.2%)
Lesion length 0.239
<10 mm 55/180 (30.6%) 56/182 (30.8%)
10–20 mm 91/180 (50.6%) 103/182 (56.6%)
>20 mm 34/180 (18.9%) 23/182 (12.6%)
Calcification
Little or none 170/204 (83.3%) 183/213 (85.9%)
Moderate or heavy 34/204 (16.7%) 30/213 (14.1%)
Angulation 0.786
None 175/181 (96.7%) 174/183 (95.1%)
Moderate 6/181 (3.3%) 8/183 (4.4%)
Severe 0/181 (0.0%) 1/183 (0.5%)
Modified ACC/AHA lesion type 0.683
A 4/214 (1.9%) 4/219 (1.8%)
B1 39/214 (18.2%) 33/219 (15.1%)
B2 127/214 (59.3%) 142/219 (64.8%)
C 44/214 (20.6%) 40/219 (18.3%)
Bifurcation 0.299
No side branch involvement 94/182 (51.6%) 86/186 (46.2%)
Side branch involvement 88/182 (48.4%) 100/186 (53.8%)
Ostial location 51/178 (28.7%) 57/182 (31.3%) 0.581
Stent placement 225/229 (98.3%) 234/237 98.7%) 0.720
Direct stenting 69/225 (30.7%) 83/234 (35.5%) 0.274
Balloon size (mm) 2.80±0.42 2.80±0.43 0.935
Total number of stents 1.22±0.48 1.18±0.42 0.392
Maximal stent diameter (mm) 3.13±0.41 3.14±0.42 0.878
Total stent length (mm) 22.80±10.34 22.34±8.97 0.717
Values are the number of cases (%) or mean±SD.
ACC/AHA, American College of Cardiology/American Heart Association; BMI, body mass index; CABG, coronary artery bypass graft; CX, left
circumflex artery; IRV, infarct-related vessel; LAD, left anterior descending artery; LM, left main artery; MI, myocardial infarction; PCI,
percutaneous coronary intervention; RCA, right coronary artery.
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In STEMI, Laarman et al7 found no signiﬁcant beneﬁt
associated with the use of ﬁrst-generation
paclitaxel-eluting stents in primary PCI as compared
with uncoated stents with the same design. Spaulding
et al,13 however, found a signiﬁcant reduction in the inci-
dence of target-vessel failure at 1 year, using a
sirolimus-eluting stent, compared with uncoated stents.
Rates of stent thrombosis were similar in the coated and
uncoated stent groups in both studies.
In the EXAMINATION trial, an allcomer trial in 1498
patients with STEMI comparing second-generation EES
versus BMS, Sabate et al14 showed that the rate of target
lesion revascularisation and the rate of stent thrombosis
were reduced in recipients of EES. The same result on
stent thrombosis was found in a subgroup of patients
with NSTE-ACS from the BASKET-PROVE trial;15
however, neither trial was sufﬁciently powered for this
end point and the latter was a post hoc analysis.
Table 4 Angiographic results preprocedural and postprocedural and at 9 months follow-up
EES (n=85) BMS (n=87) p Value
Pre-PCI
Time from randomisation to PCI (hours) 26.4±40.2 41.7±67.3 0.075
MLD (mm) 0.81±0.42 0.81±0.40 0.928
Diameter stenosis (%) 69.73±15.28 69.00±14.92 0.711
Lesion length (mm) 14.43±6.63 13.39±7.03 0.234
Reference diameter pre-PCI (mm) 2.73±0.52 2.65±0.55 0.304
Post-PCI
MLD (mm) 2.36±0.57 2.30±0.46 0.163
Diameter stenosis (%) 11.85±16.75 13.06±10.80 0.107
Lesion length (mm) 18.30±7.88 17.58±7.08 0.709
Stent placement 82/84 (97.6%) 87/89 (97.8%) >0.99
Direct stenting 27/82 (32.9%) 32/87 (36.8%) 0.599
Number of stents 1.26±0.49 1.15±0.39 0.114
Maximal stent diameter (mm) 3.14±0.43 3.13±0.45 0.660
Total stent length (mm) 22.57±10.74 21.47±7.72 0.825
Balloon size (mm) 2.82±0.45 2.69±0.45 0.084
Acute gain (mm) 1.53±0.50 1.50±0.52 0.498
Nine-month follow-up EES (n=60) BMS (n=64)
Time from randomisation to 9 months follow-up (months) 8.9±1.6 9.2±2.4 0.468
MLD (mm) 2.37±0.63 1.84±0.62 <0.001
Diameter stenosis (%) 11.25±18.03 31.13±18.65 <0.001
Binary restenosis* 1/54 (1.9%) 10/60 (16.7%) 0.007
Late loss (mm) 0.09±0.52 0.52±0.51 <0.001
Values are mean±SD or count/sample size (%).
*diameter stenosis at 9 months follow-up >50%.
Acute gain, MLD after stenting minus MLD at baseline; Late loss, MLD after stenting minus MLD at follow-up; MLD, minimal lumen diameter.
BMS, bare-metal stent; EES, everolimus-eluting stent; PCI, percutaneous coronary intervention.
Figure 2 Kaplan-Meier curves showing freedom from MACE up to 720 days after the index procedure in the pooled population.
MACE, major adverse cardiac events (composite of death, myocardial infarction and target vessel revascularisation).
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Although there is growing evidence that the cobalt-chro-
mium (CoCr)-EES is safe, there is still debate about the
relative safety of DES compared to BMS related to stent
thrombosis. Pathological studies suggest that the per-
manent presence of polymers may result in chronic
arterial inﬂammation, resulting in delayed endothelial
healing and late thrombotic events.16
A large meta-analysis in 2007 comparing BMS and ﬁrst-
generation DES strengthened concerns about late and
very late stent thrombosis with paclitaxel-eluting stents.17
Recently, however, it has been shown that second-
generation polymers (ie, polyvinylidene ﬂuoride-co-hexa-
ﬂuoropropene (PVDF-HFP)) used in current DES
provide a more biocompatible surface than early-
generation polymers18 and Kolandaivelu et al19 showed in
a controlled model of early ST that drug-eluting polymer-
coated stents are even consistently less, not more,
thrombogenic than matched bare metal platforms.
Continuous reﬁnement in stent design and the devel-
opment of thinner stent struts has resulted in signiﬁ-
cantly lower rates of stent thrombosis; thus nowadays
even larger sample sizes are required to accurately
estimate differences between stents and as such many
RCTs are presently underpowered for this endpoint.
For this reason, Palmerini et al20 conducted a large
network meta-analysis of RCTs comparing the risk of
thrombosis between bare-metal, ﬁrst-generation and
second-generation DES. They reported a profound
reduction of stent thrombosis with cobalt-chromium
EES, compared with other DES as well as with BMS at
2-year follow-up. These ﬁndings were corroborated by
the results of another meta-analysis of 4896 patients
comparing the cobalt-chromium EES with its uncoated
otherwise identical metallic counterpart, showing
improvement in cardiovascular outcomes including
cardiac survival, MI and overall stent thrombosis with
the cobalt-chromium EES.21
The issue of restenosis is often thought of as trivial, not
having any inﬂuence at clinical end points, but there is
evidence that in ∼10% of cases, patients with in-stent
restenosis present with reMI instead of just angina.22
In our study, restenosis rates were highly signiﬁcantly
lower in the EES group at 9 months angiographic follow-up,
which is consistent with ﬁndings in previous trials.
Our study, however, is the ﬁrst randomised trial to
investigate the safety and efﬁcacy of second-generation
DES in a NSTEMI population. Patients with NSTEMI
differ from those with STEMI. In STEMI, the culprit
artery is usually occluded by a thrombus, whereas in
NSTEMI the culprit artery is usually patent with a non-
occlusive thrombus, but both conditions stem from the
same pathophysiological process.10 23 24 Thereby,
patients with STEMI are older and have more comorbid-
ity as compared to patients with STEMI, reﬂecting their
worse long-term clinical outcome. This study shows that
Figure 3 Kaplan-Meier curves showing freedom from stent thrombosis up to 720 days after the index procedure in the pooled
population.
Table 5 MACE, TVR and ST at 2 years follow-up
Follow-up at 2 years EES (%) BMS (%) p Value
Elisa-3 (n=173)
MACE 10.7 14.6 0.442
TVR 4.8 11.2 0.119
ST 1.2 3.4 0.621
Elisa Registry (n=282)
MACE 13.6 16.9 0.437
TVR 3.6 9.9 0.035
ST 1.4 2.8 0.684
Pooled Analysis (n=455)
MACE 12.5 16.0 0.284
TVR 4.0 10.4 0.009
ST 1.3 3.0 0.339
BMS, bare-metal stent; EES, everolimus-eluting stent; MACE,
major adverse cardiac events (composite of death, myocardial
infarction and target vessel revascularisation); TVR, target vessel
revascularisation; ST, stent thrombosis.
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DE stenting in this patient population is safe and
improves long-term target vessel revascularisation.
Limitations of the study
Several limitations of the present study should be
acknowledged. Most important was the lower than
expected inclusion rate in the ELISA-3 angiographic
substudy. When inclusion in the main study was ﬁnished,
of 344 eligible patients only 178 were randomised in this
angiographic substudy, giving an ∼78% power to prove
superiority of the DES, while we anticipated to recruit
280 patients in our power calculations.
Furthermore, we encountered a higher than expected
loss of angiographic follow-up at 9 months. We con-
ducted a pooled analysis of the ELISA-3 and the ELISA
Registry patients to have more power with regard to the
safety of DE versus BM stenting in terms of clinical
outcome; this study, however, was not powered to show
differences in MACE.
Conclusion
In patients with NSTEMI, the use of an EES second-
generation DES is safe and decreases both angiographic
and clinical restenosis as compared to a cobalt chro-
mium BMS.
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